<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1416">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740372</url>
  </required_header>
  <id_info>
    <org_study_id>REK Norway: 171640</org_study_id>
    <nct_id>NCT04740372</nct_id>
  </id_info>
  <brief_title>Development of an International COVID-19 Specific Quality of Life Questionnaire, Phase III. The OSLO COVID-19 QLQ</brief_title>
  <official_title>Development of an International Questionnaire to Assess Patient-reported Quality of Life Related to COVID-19 Disease, the Oslo COVID-19 Quality of Life Questionnaire (QLQ) - ## © Phase III of Questionnaire Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio de Navarro de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the East Ramon Magsaysay Memorial Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sumandeep Vidyapeeth</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Birzeit University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Centre for Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Komfo Anokye Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: to develop an international validated patient-reported outcome measure for COVID-19&#xD;
      patients according to international guidelines.&#xD;
&#xD;
      In this phase III of the project, the preliminary questionnaire of 80 items will be tested.&#xD;
      It has been developed based on literature review and interviews with health care&#xD;
      professionals and patients (phase I-II).&#xD;
&#xD;
      In Phase III A patients will fill in the questionnaire followed by interviews on relevance,&#xD;
      importance and wording of the questionnaire In Phase III B patients will fill in the&#xD;
      questionnaire and an debriefing questionnaire. We will do explorative psychometric analyses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aim to develop an international validated patient-reported outcome measure for&#xD;
      COVID-19 patients according to international guidelines. The Phase I and II of this&#xD;
      development process have been finalized. Based on a systematic literature review , interviews&#xD;
      with 44 health-care professionals and 52 patients in 6-7 countries a final list of 80&#xD;
      questions, the preliminary Oslo COVID-19 QLQ - PW80 ©, is ready to be tested in the current&#xD;
      Phase III of the development process.&#xD;
&#xD;
      The objectives of the phase III are:&#xD;
&#xD;
        -  In a limited patient group, to check that the items make sense to the target population,&#xD;
           that the phrasing and sequence of questions is acceptable, that there are no missing&#xD;
           issues and that none of the questions are confusing and/or offensive (Phase IIIA).&#xD;
&#xD;
        -  In addition, in a larger patient group, to test hypothesized subscales for psychometric&#xD;
           properties including reliability, prevalence and variance (e.g. Cronbach's alpha&#xD;
           coefficient and correlation-based methods) (Phase IIIB).&#xD;
&#xD;
      The end-product, the international COVID-19- specific questionnaire, will be a&#xD;
      psychometrically robust patient-reported outcome measure (PROM) to assess HRQoL in patients&#xD;
      with or after COVID-19 disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validated COVID-19 specific questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Instrument that can be used in international intervention and observational studies on patients with COVID-19 disease</description>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Covid19, Patient Reported Outcome Measures, Quality of Life</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention. Method study. Psychometric testing</intervention_name>
    <description>Patients will fill in the questionnaire followed by an interview (phase IIIA) or a debriefing questionnaire (Phase IIIB)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        To ensure content validity of the final questionnaire, the participants will be recruited&#xD;
        according to specified recruitment matrices based on countries, language groups, age,&#xD;
        gender, hospitalisation status, disease status and comorbidity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with verified SARS-CoV-2 infection (positive test according to local/national&#xD;
             standards)&#xD;
&#xD;
          -  Patients with active or previous symptomatic COVID-19 disease&#xD;
&#xD;
          -  In-patients in hospitals and nursing homes or out-patients in hospitals or patients&#xD;
             discharged from institutions to their home/covid-19 centres or patients staying at&#xD;
             home/covid-19 centres during the course of the disease&#xD;
&#xD;
          -  Patients aged 18 years and older&#xD;
&#xD;
          -  Ability to read and comprehend the process and study documents as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in intensive care units (can be recruited after they have been dismissed)&#xD;
&#xD;
          -  Inability to read and comprehend the process and study documents as judged by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cecilie D Amdal, PhD</last_name>
    <phone>+4791517199</phone>
    <email>cecia@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Bjordal, PhD</last_name>
    <email>kbj@ous-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilie D Amdal, PhD</last_name>
      <phone>+4791517199</phone>
      <email>cecia@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Cecilie Delphin Amdal</investigator_full_name>
    <investigator_title>Head of PROMiNET, Research support service</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

